CRIS News 2.29 Curis Inc (CRIS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Curis Inc (CRIS) 2.29 $CRIS

Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.

Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
PR Newswire - Tue Apr 08, 2:30AM CDT
Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients.

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:36PM CDT
CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014
GlobeNewswire - Mon Apr 07, 3:02PM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients.

Curis to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 6:19AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13 Annual Needham Healthcare Conference at 1:40 p.m. ET on April 9, 2014, in New York City.

FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge
Ben Fidler, The Motley Fool - Motley Fool - Mon Mar 31, 12:17PM CDT
Curis ' cancer drug just got a second lease on life. Now the Lexington, Mass.-based company will have to make something of it. Curis said today that the FDA has  lifted the partial clinical hold on CUDC-427 , the experimental cancer drug it...

Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Today’s Top Biotech Stories: Curis, Amgen, and Novartis
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 31, 8:31AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four biotech stocks -- Curis , Amgen ...

Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427
GlobeNewswire - Mon Mar 31, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.

Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5 to 9 in San Diego, CA. Curis researchers will present data for two of its proprietary targeted cancer drug candidates, CUDC-907, a dual HDAC and PI3K inhibitor and CUDC-427, an antagonist of IAP proteins.

Stock to Watch: Curis Down 7.5% (CRIS)
Comtex SmarTrend(R) - Mon Mar 24, 10:43AM CDT
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 7.5% to $2.86 on 1.1x average daily volume. Curis has traded 594,000 shares thus far today, vs. average volume of 535,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.3%) and underperformed the S&P 500 (-7.5% to the S&P's -0.7%) during today's trading.

Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.

Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.

Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.

Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).

Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.

Curis Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Feb 20, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported its financial results for the fourth quarter and year ended December 31, 2013.

Curis to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire - Wed Feb 19, 3:15PM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the RBC Capital Markets Global Healthcare Conference at 1:35 p.m. ET on February 26, 2014, in New York City.

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014
GlobeNewswire - Thu Feb 13, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Thursday, February 20, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Standard Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2013.

Curis to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Leerink Global Healthcare Conference at 10:40 a.m. ET on February 12, 2014, in New York City.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 13

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 75

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 170

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 111

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 40

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Consumer Trust: The Most Trusted Brands of 2026

Updated Category News Views 270

Consumer Trust at the Core of Shopping Decisions In an ever-competitive marketplace, consumers face an overwhelming array of choices, making decisions increasingly challenging. Fortunately, trust acts as a guiding beacon for shoppers, allowing them to confidently narrow down their options when making purchases. According to the BrandSpark American Trust Study, a...

Continue Reading
Saudi AI Hackathon 2025: Empowering Student Innovators

Updated Category News Views 215

Saudi AI & Edge Computing Hackathon 2025 Fosters Innovation In a remarkable showcase of talent and creativity, the Saudi AI & Edge Computing Hackathon 2025 took center stage, emphasizing the synergy between academia and the tech industry. Hosted by Prince Sultan University and backed by MemryX, this hackathon highlighted the exceptional capabilities of students from...

Continue Reading
Meta Implements AI Hiring Freeze Amid Talent Competition

Updated Category News Views 312

Meta Platforms Inc. Takes a Step Back in AI Hiring Meta Platforms Inc. (NASDAQ: META) has recently instituted a hiring freeze in its artificial intelligence division. This decision follows months of aggressive recruitment, during which the company significantly boosted its talent pool with substantial compensation offers. The freeze is aimed at regulating the hiring...

Continue Reading
Lady Gaga's Heartfelt Cover of 'Won't You Be My Neighbor?' in Super Bowl Teaser

Updated Category News Views 148

Lady Gaga Celebrates Community with New Cover In a touching tribute to the spirit of neighborliness, Lady Gaga has graced the world with her cover of "Won't You Be My Neighbor?". This initiative is part of a larger campaign that dives deep into themes of home, community, and belonging. Behind the Scenes of the Teaser Fans can catch exclusive behind-the-scenes footage...

Continue Reading
Palo Alto Networks Plummets: Guidance Cut or Market Misread?

Updated Category News Views 245

Palo Alto Networks took a nosedive, with shares down over 7% premarket, sitting at $151.69—a shocker for traders who were banking on bullish momentum. The cybersecurity giant's fiscal second-quarter report dropped Tuesday, revealing a mixed bag that left investors scrambling to recalibrate expectations. While the top line reported $2.59 billion in revenue—just edging...

Continue Reading